ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Cardiac failure,Heart failures NEC,Heart failures,Card,Y
1,2,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
1,3,Inflammation,Inflammations,General system disorders NEC,Genrl,N
1,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
1,5,Neutrophil count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
1,6,Peripheral swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
1,7,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
2,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
3,1,Drug interaction,Interactions,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
3,2,Muscle spasms,Muscle related signs and symptoms NEC,Muscle disorders,Musc,N
3,3,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
4,1,Neuropathy peripheral,Peripheral neuropathies NEC,Peripheral neuropathies,Nerv,N
4,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
5,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
5,2,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
6,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
7,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
7,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
7,3,Prescribed underdose,Underdoses NEC,Overdoses and underdoses NEC,Inj&P,N
7,4,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
7,5,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
8,1,Headache,Headaches NEC,Headaches,Nerv,N
9,1,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
9,2,Drug intolerance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
9,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
9,4,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
10,1,Drug-induced liver injury,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
11,1,Anxiety,Anxiety symptoms,Anxiety disorders and symptoms,Psych,N
11,2,Feeling abnormal,Feelings and sensations NEC,General system disorders NEC,Genrl,N
11,3,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
11,4,Suicidal ideation,Suicidal and self-injurious behaviour,Suicidal and self-injurious behaviours NEC,Psych,N
12,1,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
12,2,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
13,1,Inappropriate schedule of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
13,2,Incorrect dose administered,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
13,3,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
14,1,Nervous system disorder,Nervous system disorders NEC,Neurological disorders NEC,Nerv,N
14,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
15,1,Drug level increased,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
15,2,Hepatotoxicity,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
15,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
16,1,Nervous system disorder,Nervous system disorders NEC,Neurological disorders NEC,Nerv,N
16,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
17,1,Lung disorder,Respiratory tract disorders NEC,Respiratory disorders NEC,Resp,N
17,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
18,1,Hepatotoxicity,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
18,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
19,1,Gastrointestinal disorder,Gastrointestinal disorders NEC,Gastrointestinal conditions NEC,Gastr,N
19,2,Nervous system disorder,Nervous system disorders NEC,Neurological disorders NEC,Nerv,N
19,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
20,1,Nervous system disorder,Nervous system disorders NEC,Neurological disorders NEC,Nerv,N
20,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
21,1,Nervous system disorder,Nervous system disorders NEC,Neurological disorders NEC,Nerv,N
21,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
22,1,Eye disorder,Ocular disorders NEC,Eye disorders NEC,Eye,N
22,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
22,3,Skin disorder,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
23,1,Hepatotoxicity,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
23,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
24,1,Hepatitis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
24,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
25,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
25,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
26,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
26,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
27,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
27,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
28,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
28,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
29,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
29,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
30,1,Intestinal perforation,Intestinal ulcers and perforation NEC,Gastrointestinal ulceration and perforation,Gastr,Y
30,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
31,1,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
31,2,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
32,1,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
32,2,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
33,1,Drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
33,2,Febrile neutropenia,Neutropenias,White blood cell disorders,Blood,N
34,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
34,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
34,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
34,4,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
35,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
35,2,Intentional product use issue,Intentional product use issues,Off label uses and intentional product misuses/use issues,Inj&P,N
35,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
36,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
36,2,Diarrhoea,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
36,3,Enterococcal infection,Enterococcal infections,Bacterial infectious disorders,Infec,N
36,4,Metapneumovirus infection,Viral infections NEC,Viral infectious disorders,Infec,N
36,5,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
37,1,Cardiac disorder,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
37,2,Electrocardiogram QT prolonged,ECG investigations,Cardiac and vascular investigations (excl enzyme tests),Inv,N
38,1,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,Y
38,2,Myocardial ischaemia,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
39,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
40,1,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
40,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
41,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
42,1,Drug effective for unapproved indication,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
42,2,Skin lesion,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
43,1,Aspergillus infection,Aspergillus infections,Fungal infectious disorders,Infec,N
43,2,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
43,3,Haemoptysis,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
43,4,Melaena,Non-site specific gastrointestinal haemorrhages,Gastrointestinal haemorrhages NEC,Gastr,N
43,5,Mucormycosis,Fungal infections NEC,Fungal infectious disorders,Infec,N
44,1,Cardiotoxicity,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
44,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
45,1,Hepatotoxicity,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
45,2,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
46,1,Hepatotoxicity,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
47,1,Hepatotoxicity,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
48,1,Hepatotoxicity,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
49,1,Delirium,Deliria,Deliria (incl confusion),Psych,N
49,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
50,1,Gastrointestinal toxicity,Gastrointestinal inflammatory disorders NEC,Gastrointestinal inflammatory conditions,Gastr,N
51,1,Drug ineffective for unapproved indication,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
51,2,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
51,3,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
52,1,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
52,2,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
53,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
53,2,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
53,3,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
54,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
54,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
55,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
55,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
56,1,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
56,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
57,1,Headache,Headaches NEC,Headaches,Nerv,N
57,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
58,1,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
58,2,Gastrointestinal toxicity,Gastrointestinal inflammatory disorders NEC,Gastrointestinal inflammatory conditions,Gastr,N
58,3,Influenza like illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
58,4,Taste disorder,Sensory abnormalities NEC,Neurological disorders NEC,Nerv,N
59,1,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
59,2,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
59,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
60,1,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
60,2,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
61,1,Headache,Headaches NEC,Headaches,Nerv,N
61,2,Insomnia,Disturbances in initiating and maintaining sleep,Sleep disorders and disturbances,Psych,N
61,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
62,1,Cardiotoxicity,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
62,2,Cardiotoxicity,Cardiac disorders NEC,"Cardiac disorders, signs and symptoms NEC",Card,N
62,3,Chest discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
62,4,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
62,5,Dysuria,Bladder and urethral symptoms,Urinary tract signs and symptoms,Renal,N
62,6,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
62,7,Proctitis,Rectal inflammations NEC,Gastrointestinal inflammatory conditions,Gastr,N
62,8,Swelling face,General signs and symptoms NEC,General system disorders NEC,Genrl,N
63,1,Adverse reaction,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
64,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
64,2,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
64,3,Infusion related reaction,Non-site specific procedural complications,Procedural related injuries and complications NEC,Inj&P,N
65,1,Aspergillus infection,Aspergillus infections,Fungal infectious disorders,Infec,N
65,2,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
65,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
66,1,Blindness,Visual impairment and blindness (excl colour blindness),Vision disorders,Eye,N
66,2,Central nervous system infection,Central nervous system and spinal infections,Infections - pathogen unspecified,Infec,N
66,3,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
66,4,Drug level below therapeutic,Therapeutic drug monitoring analyses,Toxicology and therapeutic drug monitoring,Inv,N
67,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
67,2,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
68,1,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
69,1,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
70,1,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
71,1,Hepatotoxicity,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
